Tasmar Related Published Studies
Well-designed clinical trials related to Tasmar (Tolcapone)
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. [2002.03.01]
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. [2001.09]
Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. [2001.07]
Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone. [2001.02]
The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. [2000.05]
Lack of interaction between tolcapone and tolbutamide in healthy volunteers. [2000.05]
Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism. [2000.03]
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. [2000.01]
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine. [2000]
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease. [1999]
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. [1998.08]
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. [1998.07]
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. [1998.07]
Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. [1998.05]
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. [1998.05]
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. [1998.05]
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. [1997.12]
Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). [1997.11]
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. [1997.10]
Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. [1997.10]
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. [1997.09]
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. [1997.01]
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. [1997]
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. [1996]
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. [1995.09]
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. [1995.06]
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. [1995.05]
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. [1995.05]
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. [1993.12]
Well-designed clinical trials possibly related to Tasmar (Tolcapone)
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease. [2003.06]
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. [1995.08]
Other research related to Tasmar (Tolcapone)
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. [2008.03]
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. [2008.02]
Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease. [2008]
Role of tolcapone in the treatment of Parkinson's disease. [2007.12]
Tolcapone: an efficacy and safety review (2007). [2007.09]
Results from a 2-year centralized tolcapone liver enzyme monitoring program. [2007.09]
Tolcapone improves cognition and cortical information processing in normal human subjects. [2007.05]
Safety and tolerability of adjunctive Tolcapone therapy in early Parkinson's disease patients. [2006.11.21]
Tolcapone in the management of Parkinson's disease. [2006.11]
Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects. [2006.10.25]
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. [2006.06]
[Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example] [2005.11]
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. [2005.04]
Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. [2005.01]
Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. [2005]
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. [2003.09]
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. [2003.08]
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. [2003.02]
Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. [2003]
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. [2001.09]
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. [2001]
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. [2001]
[Akathisia secondary to tolcapone. Report of a case] [2000.09]
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. [2000.06]
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. [2000.05]
Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. [2000.02]
Tolcapone increases maximum concentration of levodopa. [2000]
Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. [1999.12]
Tolcapone: a novel approach to Parkinson's disease. [1999.11.01]
Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. [1999.10]
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). [1999.09]
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. [1999.08]
The effect of tolcapone on the pharmacokinetics of benserazide. [1999.03]
Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. [1999.01]
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. [1999.01]
Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. [1998.06]
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. [1998.05]
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. [1998.04]
[Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease] [1998.02]
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. [1997.09]
Cognitive improvement during Tolcapone treatment in Parkinson's disease. [1997]
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. [1997]
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. [1995.06.16]
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. [1994.10.15]
The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats. [1994.07]
Other possibly related research studies
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. [2005]
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. [2005.05]
The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites. [2005]
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. [2004.09]
Safety and tolerability of COMT inhibitors. [2004.01.13]
Prevention and treatment of motor fluctuations. [2003.08]
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. [2003.05]
The relevance of preclinical studies for the treatment of Parkinson's disease. [2003.02]
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. [2002]
[The usefulness of dopaminergic drugs in traumatic brain injury] [2002.08.16]
Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. [2002.07]
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. [2002]
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. [2001]
[Pharmacological treatments of Parkinson's disease] [2001.02]
The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. [2000]
Practical issues with COMT inhibitors in Parkinson's disease. [2000]
COMT inhibitors and liver toxicity. [2000]
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials. [2000]
Issues important for rational COMT inhibition. [2000]
[A prospect of treatment for Parkinson's disease in the 21st century] [2000.10]
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. [2000.06]
[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone] [2000.02]
New drugs for the treatment of Parkinson's disease. [2000.01]
|
